Fabre-Kramer Submits NDA Amendment for EXXUA™ for Treatment of Major Depressive Disorder

/PRNewswire/ -- Fabre-Kramer Pharmaceuticals, Inc. (Fabre-Kramer) today announced that on December 23, 2022, it filed an NDA Amendment with the Food and Drug...

Related Keywords

California ,United States ,Houston ,Texas ,Stephen Kramer ,Anitah Clayton ,Stephena Stahl ,University Of California ,Linkedin ,Department Of Psychiatry Neurobehavioral Sciences ,Human Services ,Drug Administration ,Neuroscience Education Institute ,University Of Virginia School Medicine ,Us Department Of Health ,Fabre Kramer Pharmaceuticals Inc ,New Class ,Novel Mechanism Uniquely ,Directly Addresses Important Unmet ,Fabre Kramer Pharmaceuticals ,Major Depressive Disorder ,Neurobehavioral Sciences ,Virginia School ,Nc ,